Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 29Multiple Myeloma 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Lymphoma 20Melanoma 16Lymphoma, Non-Hodgkin 14Colorectal Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Wilms Tumor 11Myelodysplastic Syndromes 10Lung Neoplasms 10Hodgkin Disease 10Squamous Cell Carcinoma of Head and Neck 9Sarcoma 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Carcinoma, Renal Cell 9Burkitt Lymphoma 9Rhabdomyosarcoma 8Rhabdoid Tumor 8Neoplasms 8Leukemia 8Hepatoblastoma 8Glioma 8Colonic Neoplasms 8Sarcoma, Ewing 7Osteosarcoma 7

Interventions

Sorafenib 1Mitoxantrone 1Leyk 1Etoposide 1Daunorubicin 1Cytarabine 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Myeloid × 30 days × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡